- Pin
- 🎁 12th Anniversary Celebration – Reward Distribution Notification
🎊 Congratulations to all winners! Rewards have been sent to your Gate accounts. Please check your balances
Note:
- In regions where shipping isn’t available, physical merch will be converted to equivalent vouchers — please be patient;
- If an item is out of stock, it will be substituted with merch of equal value.
🚀 Thank you for your support! Stay tuned for more exciting events
- What are Gate Post Ambassadors? One article guides you through the responsibilities and benefits of being a Gate Post ambassador!👇️
Fuhong Hanlin: Grants Alvogen Korea exclusive license for Hans.
Jin10 Data reported on April 25 that Fuhong Hanlin announced that the company has entered into a licensing protocol with Alvogen Korea Co., Ltd., granting it exclusive rights to commercialize Hanshuang (Srilumab injection) in South Korea. Under the protocol, Alvogen Korea will pay an upfront payment of $5 million, with regulatory milestone payments not exceeding $9.5 million, commercial sales milestone payments not exceeding $97.5 million, and tiered royalties calculated based on annual net sales ranging from 18% to 25%. The licensing protocol will take effect from the date of signing and will initially last until the 10th anniversary of the first commercial sale of the licensed product.